The initial success of the copyright undeniably revolutionized the pharmaceutical landscape, but investing in companies strongly reliant on generic versions presents a challenging picture. Despite early profits were impressive, the cessation of patents and the rise of discounted alternatives have diminished sales. Consequently, a thorough evaluatio